However, other selective and potent NOS2 inhibitor compounds, such as GW274150 (48), which was used in completed several phase 2 clinical studies in migraine, asthma, and rheumatoid arthritis (DrugBank DB12237), could represent clinical candidates for HI treatment. The gene discussed is NOS2; the disease is rheumatoid arthritis.